Skip to main content
Valiant Laboratories Limited logo

Valiant Laboratories Limited — Investor Relations & Filings

Ticker · VALIANTLAB ISIN · INE0JWS01017 LEI · 335800VKNJKWJ4LD6855 BSE.NS Manufacturing
Open in API
Filings indexed 173 across all filing types
Latest filing 2023-11-27 Capital/Financing Update
Country IN India
Listing BSE.NS VALIANTLAB

About Valiant Laboratories Limited

https://www.valiantlabs.in/

Valiant Laboratories Limited specializes in the manufacturing of Active Pharmaceutical Ingredients (APIs) and bulk drugs, with a primary focus on the production of Paracetamol. The company operates dedicated manufacturing facilities designed for the large-scale synthesis of analgesic and antipyretic compounds. By maintaining rigorous quality control standards and process efficiencies, it serves as a key supplier for formulations across various therapeutic segments. Its core business activities encompass the chemical processing and distribution of high-grade medicinal ingredients, catering to a diverse range of healthcare manufacturers. The organization prioritizes technical excellence in API synthesis and the optimization of production workflows to ensure a consistent supply of essential pharmaceutical components.

Recent filings

Filing Released Lang Actions
Credit Rating
Capital/Financing Update Classification · 95% confidence The document is an official communication from Valiant Laboratories Limited to stock exchanges (BSE and NSE) regarding the reaffirmation of credit ratings by CRISIL Ratings Limited for the company's long-term and short-term loan facilities. It includes details of the ratings, rating actions, and bank-wise facility details. The document is a notification of credit rating updates, which is a form of capital/financing update as it relates to the company's borrowing facilities and creditworthiness. It is not a full financial report, audit report, or earnings release, nor is it a regulatory filing or announcement of a report publication. The content fits best under Capital/Financing Update (CAP) as it informs stakeholders about the credit rating status, which impacts the company's financing and capital structure perception.
2023-11-27 English
Copy of Newspaper Publication
Report Publication Announcement Classification · 95% confidence The document is a letter addressed to stock exchanges regarding the publication of audited financial results for the quarter and half year ended September 30, 2023. It mentions that the financial results have been published in newspapers and are also available on the company's website. The document itself does not contain the financial results or detailed financial statements but is an announcement about the publication of these results. The document length is short (1668 characters), and it serves as a notification rather than the report itself. According to the MENU VS MEAL RULE, this is a Report Publication Announcement (RPA) rather than an Interim/Quarterly Report (IR) or Earnings Release (ER).
2023-11-08 English
Financial Result Updates
Regulatory Filings
2023-11-06 English
Board Meeting — VALIANT LABORATORIES LIMITED has informed the Exchange about Board Meeting to be held on 06-Nov-2023 to inter-alia consider and approve the Audited Financial results of the Company fo…
Regulatory Filings
2023-10-30 English
Board Meeting — Financial Results
Regulatory Filings Classification · 95% confidence The document is a short notice informing the stock exchanges about an upcoming Board Meeting scheduled for November 6, 2023. The purpose of the meeting includes considering and approving the audited financial results for the quarter and half year ended September 30, 2023. The document references Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure of events or information by listed entities. The document is an intimation or announcement of a Board Meeting and not the actual financial results or report. It is also under 5,000 characters and does not contain any financial data or detailed report. Therefore, it is best classified as a Regulatory Filing (RNS) as a general regulatory announcement about the Board Meeting and upcoming financial results approval, rather than the financial report itself or a management change announcement.
2023-10-30 English
Acquisition
Capital/Financing Update Classification · 100% confidence The document is a formal communication addressed to stock exchanges (BSE and NSE) regarding an investment in a wholly-owned subsidiary company. It references Regulation 30 of SEBI (LODR) Regulations, 2015, which pertains to disclosure of material events. The content details the acquisition of shares in a subsidiary, including the nature of the transaction, consideration, and background information about the subsidiary. There is no financial statement or comprehensive financial report included, nor is there any indication of earnings results, management discussion, or audit information. The document is an announcement of a capital investment transaction and related disclosures as required by listing regulations. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes.
2023-10-23 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.